Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nimotuzumab + paclitaxel + cisplatin
- Development stage
- Phase 3
- Lead developer
- Gilead Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of nimotuzumab (a humanized anti-EGFR monoclonal antibody), paclitaxel (a taxane chemotherapy agent), and cisplatin (a platinum-based chemotherapy agent). This regimen is primarily used for the treatment of advanced esophageal squamous cell carcinoma (ESCC). The combination has demonstrated significant antitumor activity with objective response rates of approximately 51.8-54.7% and disease control rates of 92.9-94.3% in clinical trials.
- Other names
- TPN regimenTCN regimen
02
Targets
Beyond the preview
Go deeper on nimotuzumab + paclitaxel + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nimotuzumab + paclitaxel + cisplatin.